While FLOW excluded participants < 18 years of age, it is likely GLP-1R agonists and other weight modification medications will play some role in the future management of children with obesity that is unresponsive to lifestyle measures and causing complications such as hypertension or diabetes [87]. Here, GLP1R is linked to obesity disorder.